{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:43:51Z","timestamp":1791607431819,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"LEO Pharma"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jaad.2020.04.129","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:52:54Z","timestamp":1588161174000},"page":"1088-1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action"],"prefix":"10.1016","volume":"83","author":[{"given":"Jade G.M.","family":"Logger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill I.","family":"Olydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke J.B.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.04.129_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.15122","article-title":"Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments","volume":"181","author":"van Zuuren","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2340\/00015555-2335","article-title":"Facial erythema of rosacea\u2014aetiology, different pathophysiologies and treatment options","volume":"96","author":"Steinhoff","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.04.129_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1152\/japplphysiol.00298.2010","article-title":"Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans","volume":"109","author":"Charkoudian","year":"2010","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.jaad.2020.04.129_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2020.04.129_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2020.04.129_bib8","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib9","first-page":"1201","article-title":"topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials","volume":"17","author":"Stein-Gold","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib10","first-page":"1","article-title":"Difference in vasoconstrictors: oxymetazoline vs. brimonidine","author":"Okwundu","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.04.129_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/jdv.13305","article-title":"Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study","volume":"29","author":"Layton","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.129_bib13","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","article-title":"Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial","volume":"78","author":"Draelos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib15","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/17512433.2017.1370370","article-title":"Oxymetazoline hydrochloride cream for facial erythema associated with rosacea","volume":"10","author":"Patel","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jaad.2020.04.129_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2007.01.048","article-title":"A pilot quality-of-life instrument for acne rosacea","volume":"57","author":"Nicholson","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2017.11.010","article-title":"Medical management of facial redness in rosacea","volume":"36","author":"Cline","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2020.04.129_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4103\/ijdvl.IJDVL_220_16","article-title":"Beta-blockers in dermatology","volume":"83","author":"Prabha","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2020.04.129_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jdv.14566","article-title":"The role of beta-blockers in dermatological treatment: a review","volume":"32","author":"Chen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.129_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0002-9459(24)03586-1","article-title":"Antianginal actions of beta-adrenoceptor antagonists","volume":"71","author":"O'Rourke","year":"2007","journal-title":"Am J Pharm Educ"},{"key":"10.1016\/j.jaad.2020.04.129_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.2008.08740.x","article-title":"Innervation and receptor profiles of the human apocrine (epitrichial) sweat gland: routes for intervention in bromhidrosis","volume":"159","author":"Lindsay","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/1523-1747.ep12499860","article-title":"Binding of beta-adrenergic receptors in human skin","volume":"98","author":"Steinkraus","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1067-1927.2005.130408.x","article-title":"Beta 2-adrenergic receptor activation delays dermal fibroblast-mediated contraction of collagen gels via a cAMP-dependent mechanism","volume":"13","author":"Pullar","year":"2005","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.jaad.2020.04.129_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.0022-202X.2004.23210.x","article-title":"Autocrine catecholamine biosynthesis and the beta-adrenoceptor signal promote pigmentation in human epidermal melanocytes","volume":"123","author":"Gillbro","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib27","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jaad.2013.04.041","article-title":"Emerging therapies in rosacea","volume":"69","author":"Layton","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1469-8986.1997.tb02127.x","article-title":"The effect of adrenergic blockade on blushing and facial flushing","volume":"34","author":"Drummond","year":"1997","journal-title":"Psychophysiology"},{"key":"10.1016\/j.jaad.2020.04.129_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2005.07.021","article-title":"Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol","volume":"53","author":"Craige","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0190-9622(89)70022-0","article-title":"Effect of nadolol on flushing reactions in rosacea","volume":"20","author":"Wilkin","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib31","unstructured":"PROSPERO: International prospective register of systematic reviews. Available at: https:\/\/www.crd.york.ac.uk\/prospero\/. Accessed February 14, 2020."},{"key":"10.1016\/j.jaad.2020.04.129_bib32","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2020.04.129_bib33","first-page":"CD002003","article-title":"Beta-blockers for\u00a0hypertension","volume":"1","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2020.04.129_bib34","first-page":"38","article-title":"Physical modalities for the treatment of rosacea","volume":"14","author":"Hofmann","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2020.04.129_bib35","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2020.04.129_bib36","unstructured":"Wells GA, Shea B, O'Connell D, et\u00a0al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed February 18, 2020."},{"key":"10.1016\/j.jaad.2020.04.129_bib37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2020.04.129_bib38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/archdermatol.2011.204","article-title":"Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea","volume":"147","author":"Hsu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/09546634.2017.1360991","article-title":"Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol","volume":"29","author":"Pietschke","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.129_bib40","doi-asserted-by":"crossref","first-page":"e12501","DOI":"10.1111\/dth.12501","article-title":"Severe erythematotelangiectatic rosacea with cold wave-induced epidermal necrosis treated with carvedilol combined with brimonidine gel","volume":"30","author":"Lee","year":"2017","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.129_bib41","doi-asserted-by":"crossref","first-page":"e12439","DOI":"10.1111\/dth.12439","article-title":"Combination treatment of propranolol, minocycline, and tranexamic acid for effective control of rosacea","volume":"30","author":"Kwon","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.04.129_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.12687","article-title":"Propranolol, doxycycline and combination therapy for the treatment of rosacea","volume":"42","author":"Park","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjd.12838","article-title":"Antihypertensive drugs and the risk of incident rosacea","volume":"171","author":"Spoendlin","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00128071-200203070-00005","article-title":"The management of rosacea","volume":"3","author":"Rebora","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib45","first-page":"955","article-title":"Immunologic adverse reactions of beta-blockers and the skin","volume":"18","author":"Tatu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jaad.2020.04.129_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/thx.38.2.108","article-title":"Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways","volume":"38","author":"Patakas","year":"1983","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2020.04.129_bib47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0190-9622(86)70265-X","article-title":"Drugs in exacerbation of psoriasis","volume":"15","author":"Abel","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005344-200101000-00006","article-title":"Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial","volume":"37","author":"Arumanayagam","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jaad.2020.04.129_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.103.058032","article-title":"Potent antioxidant properties of 4-hydroxyl-propranolol","volume":"308","author":"Mak","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2020.04.129_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/jidsymp.2011.9","article-title":"Rosacea: the cytokine and chemokine network","volume":"15","author":"Gerber","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2020.04.129_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","author":"Bakar","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02850193","article-title":"Potential antioxidant mechanism of action for metronidazole: implications for rosacea management","volume":"18","author":"Miyachi","year":"2001","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaad.2020.04.129_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.medcli.2009.07.016","article-title":"[Safety and tolerance of beta-blocker treatment in elderly patients with heart failure. BETANIC study]","volume":"134","author":"Yebra-Yebra","year":"2010","journal-title":"Med Clin (Barc)"},{"issue":"Suppl 6","key":"10.1016\/j.jaad.2020.04.129_bib54","first-page":"29","article-title":"State of the art: systemic rosacea management","volume":"14","author":"Schaller","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2020.04.129_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01541742","article-title":"Beta-blocker effects on sexual function in normal males","volume":"17","author":"Rosen","year":"1988","journal-title":"Arch Sex Behav"},{"key":"10.1016\/j.jaad.2020.04.129_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/bmj.1.6053.105","article-title":"Clonidine and facial flushing in rosacea","volume":"1","author":"Cunliffe","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2020.04.129_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archderm.1983.01650270029012","article-title":"Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions","volume":"119","author":"Wilkin","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib58","first-page":"687","article-title":"[Rilmenidine in rosacea: a double-blind study versus placebo]","volume":"124","author":"Grosshans","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.129_bib59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2133.1999.02744.x","article-title":"The response of erythematous rosacea to ondansetron","volume":"140","author":"Wollina","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2133.1982.tb00290.x","article-title":"Alcohol-induced rosacea flushing blocked by naloxone","volume":"107","author":"Bernstein","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib61","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2014.05.044","article-title":"Reliability of Clinician Erythema Assessment grading scale","volume":"71","author":"Tan","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2015.02.1121","article-title":"Assessment of rosacea severity: a review of evaluation methods used in clinical trials","volume":"73","author":"Hopkinson","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jaad.2004.04.013","article-title":"Measurement of the severity of rosacea","volume":"51","author":"Bamford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.129_bib64","first-page":"55","article-title":"Noninvasive objective skin measurement methods for rosacea assessment: a systematic review","volume":"182","author":"Logger","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:00Z","timestamp":1759272960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220307507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0190962220307507"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.129","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}